T. Piper, C. Schlug, U. Mareck, W. Schänzer

Investigations on changes in <sup>13</sup>C/<sup>12</sup>C ratios of endogenous urinary

steroids after pregnenolone administration.

Institute of Biochemistry, German Sport University Cologne, Germany

**Abstract** 

For the detection of possible misuse of naturally occurring anabolic androgenic steroids like

testosterone (T), anti doping laboratories use a combination of two techniques. One is

molecular steroid profiling to evaluate urinary steroid concentrations and normal diagnostic

ratios. The other is isotope ratio mass spectrometry (IRMS), in which the <sup>13</sup>C/<sup>12</sup>C ratios of

target analytes like T are compared to the <sup>13</sup>C/<sup>12</sup>C ratios of endogenous reference compounds

(ERCs). The <sup>13</sup>C/<sup>12</sup>C of the most commonly used ERC, pregnanediol (5β-pregnane-3α,20α-

diol, PD), can be influenced by administration of pregnenolone (3β-hydroxy-pregn-5-en-20-

one, PREG). Therefore PREG administration bears the potential to circumvent IRMS testing

for doping control samples.

In order to investigate the influence of PREG on PD and on other urinary excreted steroids

administration studies with oral and transdermal application of PREG were carried out. The

influence of PREG administration on concentrations and <sup>13</sup>C/<sup>12</sup>C ratios of all investigated

target analytes was negligible. Only PD and 5β-pregnan-3α-ol-20-one (3aP) showed

significant depletion in both their glucuronidated and sulfated steroids. The results suggest

that appropriate alternative ERCs are: 11β-hydroxy-androsterone/etiocholanolone, 5β-

pregnane- $3\alpha$ , 17, 20 $\alpha$ -triol, pregn-5-ene- $3\beta$ , 17, 20 $\alpha$ -triol and cholesterol.

Due to its properties to disguise the misuse of anabolic steroids by influencing the <sup>13</sup>C/<sup>12</sup>C

ratio of PD, PREG should be considered to be added to the World Anti-Doping Agency list

of prohibited substances as a masking agent.

The complete article can be found at: *Drug Test. Analysis* 2011, **3**, 283-290.

WS2011 – LECTURE

112